Get the Stockscreener App
27.07
0.29%
-0.08
Upstream Bio Inc stock is traded at $27.07, with a volume of 586.43K.
It is down -0.29% in the last 24 hours and up +8.24% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
See More
Previous Close:
$27.15
Open:
$27.3
24h Volume:
586.43K
Relative Volume:
1.25
Market Cap:
$1.46B
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-21.07
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
-8.18%
1M Performance:
+8.24%
6M Performance:
+143.22%
1Y Performance:
+66.07%
1-Day Range:
$26.72
$28.01
1-Week Range:
$26.72
$29.92
52-Week Range:
$5.14
$33.00
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
27.07 | 1.47B | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Evercore ISI | Outperform |
| Oct-14-25 | Initiated | Truist | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Upstream Bio Inc Stock (UPB) Latest News
Upstream Bio Inc Stock Price ($UPB), Quote & News - eToro
Upstream Bio initiated with an outperform at Mizuho - MSN
AI Indicators Detect Buy Opportunity in Zenith Drugs LimitedCash Flow Trends & Outstanding Investment Returns - earlytimes.in
Geopolitics Watch: How Upstream Bio Inc stock reacts to Fed rate cutsWeekly Market Report & Fast Momentum Entry Tips - moha.gov.vn
Upstream Bio (NASDAQ:UPB) Shares Down 3.4%Time to Sell? - MarketBeat
Treasury Yields: How Upstream Bio Inc stock reacts to global recession fearsBuy Signal & Reliable Breakout Forecasts - moha.gov.vn
Upstream Bio Reports Progress in Respiratory Trials - MSN
Upstream Bio (NASDAQ:UPB) Stock Price Up 4.8%Should You Buy? - MarketBeat
Upstream Bio (UPB) price target decreased by 18.03% to 51.00 - MSN
Upstream Bio (UPB): NASDAQ Biotech Index Entry Sparks the Big Rerating Debate - parameter.io
Upstream Bio, Inc.(NasdaqGS: UPB) added to NASDAQ Biotechnology Index - marketscreener.com
Upstream Bio, Inc. (NASDAQ:UPB) Receives $45.25 Average Price Target from Brokerages - Defense World
Can Upstream Bio Inc. stock weather global recessionPortfolio Risk Report & Accurate Entry and Exit Point Alerts - Улправда
Why retail investors favor Upstream Bio Inc. stockWeekly Risk Summary & Low Volatility Stock Suggestions - Улправда
Does Mizuho’s New Coverage of Upstream Bio (UPB) Reframe the Stock’s Risk‑Reward Narrative? - Sahm
How Upstream Bio Inc. stock reacts to global recession fearsNew Guidance & Risk Controlled Swing Alerts - DonanımHaber
Will Upstream Bio Inc. stock beat EPS estimatesEarnings Growth Summary & Risk Adjusted Swing Trade Ideas - Улправда
Upstream Bio (NASDAQ:UPB) Stock Rating Upgraded by Mizuho - MarketBeat
Is Upstream Bio Inc. stock overvalued by current metricsTrade Analysis Summary & Weekly Sector Rotation Insights - Улправда
How Upstream Bio Inc. stock reacts to inflationary pressures2025 Sector Review & Risk Managed Investment Strategies - DonanımHaber
Will Upstream Bio Inc. stock maintain dividend yieldQuarterly Earnings Summary & Free Real-Time Market Sentiment Alerts - DonanımHaber
Will Upstream Bio Inc. stock benefit from green energy trends2025 Top Gainers & Expert-Curated Trade Recommendations - Улправда
Chipmakers Recap: Can Upstream Bio Inc. stock weather global recessionJuly 2025 Levels & Low Risk Investment Opportunities - Улправда
Upstream Bio, Inc. (NASDAQ:UPB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Mizuho Initiates Coverage on UPB with Outperform Rating and $51 PT | UPB Stock News - GuruFocus
Mizuho initiates Upstream Bio stock with Outperform rating on asthma drug potential - Investing.com Canada
Upstream Bio initiated with an Outperform at Mizuho - TipRanks
Upstream Bio (NASDAQ:UPB) Stock Price Up 6.9%Time to Buy? - MarketBeat
Financial Analysis: Precision BioSciences (NASDAQ:DTIL) & Upstream Bio (NASDAQ:UPB) - Defense World
Bain Capital Life Sciences Investors LLC Raises Holdings in Upstream Bio, Inc. $UPB - MarketBeat
Norges Bank Acquires New Position in Upstream Bio, Inc. $UPB - MarketBeat
Can Upstream Bio Stock Hold Up When Markets Turn? - Trefis
Contrasting Upstream Bio (UPB) & The Competition - Defense World
Geode Capital Management LLC Buys 235,958 Shares of Upstream Bio, Inc. $UPB - MarketBeat
Lifesci Capital Predicts Upstream Bio FY2025 Earnings - Defense World
Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study (UPB) - Seeking Alpha
UPB: Virectib's robust phase 2 results and unique mechanism set the stage for pivotal trials in 2026 - TradingView
Lifesci Capital Forecasts Upstream Bio FY2025 Earnings - MarketBeat
Upstream Bio (NASDAQ:UPB) Shares Down 8%Here's What Happened - MarketBeat
Stocks of Upstream Bio Inc (UPB) are poised to climb above their peers - setenews.com
Upstream Bio (NASDAQ:UPB) Coverage Initiated by Analysts at Lifesci Capital - MarketBeat
Upstream Bio (NASDAQ:UPB) Now Covered by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Upstream Bio (UPB) with Outperform Recommendation - Nasdaq
Upstream Bio initiated with an Outperform at LifeSci Capital - TipRanks
Is Upstream Bio Inc. stock attractive for ETFsJuly 2025 Snapshot & Fast Moving Stock Watchlists - Newser
What analysts say about Upstream Bio Inc stockEarnings Miss Alerts & Free High Yield Market Plays - earlytimes.in
Severe Asthma Clinical Pipeline 2025: A Comprehensive Review of 50+ Emerging Therapies from 40+ Innovators, says DelveInsight - Barchart.com
You might want to take a look at Upstream Bio Inc (UPB) now - Setenews
Upstream Bio (NASDAQ:UPB) Shares Up 8.5%Should You Buy? - MarketBeat
Upstream Bio (UPB): Evaluating Valuation After 10% Share Price Surge - Yahoo Finance
Promising Outlook for Upstream Bio, Inc. Driven by Verekitug’s Clinical Advancements - TipRanks
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):